Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma

Journal of Nuclear Medicine

Volumn 48, Issue 8, 2007, Pages 1338-1347

  DeNardo, Gerald L ^a,c   Natarajan, Arutselvan ^a   Hok, Saphon ^b   Perkins, Julie ^b   Cosman, Monique ^b   DeNardo, Sally J ^a   Lightstone, Felice C ^b   Mirick, Gary R ^a   Miers, Laird A ^a   Balhorn, Rodney L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c Molecular Cancer Institute   (United States)

Author keywords

Antibody; Imaging; Lymphoma; PET; Therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMINOBENZOIC ACID DERIVATIVE; BIOTIN DERIVATIVE; DABSYLVALINE; DEOXYCHOLIC ACID; DRUG CARRIER; HLA ANTIBODY; HLA DR ANTIGEN; HLA DR10 ANTIGEN; INDIUM 111; INDIUM CHLORIDE IN 111; LEUCINE ENKEPHALIN; LIOTHYRONINE; MACROGOL; MONOCLONAL ANTIBODY LYM 1; N BENZOYLARGINYL 4 AMINOBENZOIC ACID; THYRONINE; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LYMPHOMA; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTINYLATION; FEMALE; HLA-DR ANTIGENS; HUMANS; LIGANDS; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TRANSPLANTATION, HETEROLOGOUS;

EID: 34547734419     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.041095     Document Type: Article

References (36)

1. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res. 1987;47:830-840.
2. Rose LM, Deng CT, Scott S, et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol. 1999;36:789-797.
3. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother. 1996;43:26-30.
4. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
5. 131I-Lym-1 antibody. Cancer Biother Radiopharm. 1998;13:239-254.
6. Brown KS, Levitt DJ, Shannon M, Link BK. Phase II trial of Remitogen (humanized ID10) monoclonal antibody targeting class II in patients with relapsed low-grade or folllicular lymphoma. Clin Lymphoma. 2001;2:188-190.
7. Kostelny SA, Link BK, Tso JY, et al. Humanization and characterization of the anti-HLA-DR antibody ID10. Int J Cancer. 2001;93:556-565.
8. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (apolizumab). Semin Oncol. 2002;29(1 suppl 2):81-86.
9. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002;29:38-43.
10. 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
11. Fan E, Merritt EA, Verlinde CL, Hold WG. AB(5) toxins: structures and inhibitor design. Curr Opin Struct Biol. 2000;10:680-686.
12. Kramer RH, Karpen JW. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature. 1998;395:710-713.
13. Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins. Science. 1997;278:497-499.
14. Mammen M, Choi S, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Agnew Chem Int Edit. 1998;37:2754-2794.
15. Balhorn R, Hok S, Burke P, et al. Selective high affinity ligand (SHAL) "antibody mimics" for cancer diagnosis and therapy: initial application to lymphoma/leukemia. Clin Cancer Res. In press.
16. West J, Perkins J, Hok S, et al. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm. 2006;21:645-654.
17. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res. 1997;3:71-79.
18. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J Mol Biol. 1982;161:269-288.
19. Desjarlais RL, Sheridan RP, Seibel GL, Dixon JS, Kuntz ID, Venkataraqhavan R. Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J Med Chem. 1988;31:722-729.
20. Hok S, Natarajan A, Balhorn R, DeNardo SJ, DeNardo GL, Perkins J. Synthesis and radiolabeling of selective high affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem. 2007;18:912-921.
21. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res. 1995;55:878-884.
22. DeNardo GL, DeNardo SJ, Peterson JK, et al. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res. 2003;9:3865s-3872s.
23. Fand I, McNally WP. The technique of whole-body autoradiography. In: Johnson JE, ed. Current Trends in Morphological Techniques. 1st ed. Boca Raton, FL: CRC Press; 1981:1-28.
24. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: Wiley; 1973.
25. Beyer WH, ed. CRC Handbook of Tables for Probabilities and Statistics. 2nd ed. Boca Raton, FL: CRC Press; 1968.
26. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res. 1992;52:5432s-5440s.
27. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1023-1030.
28. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
29. DeNardo GL, Sysko VV, DeNardo SJ. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys. 2006;66(2):s46-s56.
30. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
31. Witzig TE, White CA, Gordon LI. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
32. Balhorn R, Perkins SJ, Burke PA, et al. Development of selective high affinity ligand (SHAL) antibody mimics for lymphoma/leukemia imaging and therapy [abstract]. Cancer Biother Radiopharm. 2004;19(4):517.
33. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006;12:1599-1605.
34. Meares CF, Diril H, Kukis DL, et al. Radiochemistry of antibodies: some recent advances. Antibody Immunoconj Radiopharm. 1991;4:389-398.
35. 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging. 2002;29:754-759.
36. Winthrop MD, DeNardo SJ, Muenzer JT, Chi SG, Gumerlock PH. p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer. 1997;80(suppl 12):2529-2537.